Trial · NCT04771780
Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
NCT04771780, Phase 3, Completed, Kyowa Kirin Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis. Trials, record NCT04771780. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04771780
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
- NCT number
- NCT04771780
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 213 participants, actual
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Conditions
- Hyperphosphatemia
- Interventions
- KHK7791
- First posted
- 2021-02-25
- Last updated
- 2023-08-02
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence rates of all adverse events and adverse drug reactions that occurred or worsened after the initiation of KHK7791 treatment for 52 weeks. | Dose period Week 1~52 | To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia. |
| Secondary | Achievement of at least 30% change of the total number of daily prescription tablets of phosphorus binders and KHK7791 from baseline in the last 3 weeks of the final assessment. | Week 1~52 | To investigate the efficacy of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in hyperphosphatemic subjects undergoing hemodialysis. Important secondary endpoint |
| Secondary | Total daily prescription of phosphate binders and KHK7791 tablets, such as tablet counts, at each time point after the start of treatment. | Week 1~52 | |
| Secondary | Achievement of at least 30% change of the total number of daily prescription tablets of phosphorus binders and KHK7791 from baseline, at each time point after the start of treatment. | Week 1~52 | |
| Secondary | The change of total daily prescription of phosphate binders and KHK7791 tablets, such as tablet counts, at each time point after the start of treatment. | Week 1~52 | |
| Secondary | The rate of change of total daily prescription of phosphate binders and KHK7791 tablets, such as tablet counts, at each time point after the start of treatment. | Week 1~52 | |
| Secondary | Concentration of serum phosphorous levels values at each time point. | Week 1~52 | |
| Secondary | Change of serum phosphorous levels from baseline values at each time point. | Week 1~52 | |
| Secondary | Achievement/failure of the target serum phosphorus level (serum phosphorus level: ≤ 6.0). | Week 1~52 | |
| Secondary | Time when the target serum phosphorus level (serum phosphorus level: ≤ 6.0) was achieved. | Week 1~52 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04771780
GET https://conductscience.org/api/trials/v1/NCT04771780/registered